Abstract
Measuring COVID-19 spread remains challenging in many countries due to testing limitations. In Java, reported cases and deaths increased throughout 2020 despite intensive control measures, particularly within Jakarta and during Ramadan. However, underlying trends are likely obscured by variations in case ascertainment. COVID-19 protocol funerals in Jakarta provide alternative data indicating a substantially higher burden than observed within confirmed deaths. Transmission estimates using this metric follow mobility trends, suggesting earlier and more sustained intervention impact than observed in routine data. Modelling suggests interventions have lessened spread to rural, older communities with weaker healthcare systems, though predict healthcare capacity will soon be exceeded in much of Java without further control. Our results highlight the important role syndrome-based measures of mortality can play in understanding COVID-19 transmission and burden.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Centre funding from the UK Medical Research Council under a concordat with the UK Foreign, Commonwealth and Development Office and the Wellcome Trust, also under a concordat with the UK Foreign, Commonwealth and Development Office. BAD acknowledges a matched MRC Centre 1+3 studentship funding by Imperial College London School of Public Health. IRFE acknowledges a funding from Oxford University Clinical Reseach Unit (OUCRU) Strategic Committee Research for COVID-19, Vietnam. JKB, IRFE, LLE, KDL, RNL, AA, HS are supported by the Wellcome Trust, UK (106680/Z/14/Z). GT is supported by the Wellcome Trust, UK (110179/Z/15/Z). CW acknowledges funding from a UK Medical Research Council Doctoral Training Partnership (DTP) studentship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No approvals necessary
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used are publicly available from these websites: 1. https://corona.jakarta.go.id/id/data-pemantauan 2. https://covid19.go.id/peta-sebaran 3. http://kcov.id/daftarpositif 4. https://www.who.int/indonesia/news/novel-coronavirus/situation-reports
